Influence of autologous dendritic cells on cytokine‑induced killer cell proliferation, cell phenotype and antitumor activity in vitro

Cao,Jingsong; Chen,Cong; Wang,Yuhuan; Chen,Xuecheng; Chen,Zeying; Luo,Xiaoling

doi:10.3892/ol.2016.4839

Influence of autologous dendritic cells on cytokine‑induced killer cell proliferation, cell phenotype and antitumor activity in vitro

Authors:
- Jingsong Cao
- Cong Chen
- Yuhuan Wang
- Xuecheng Chen
- Zeying Chen
- Xiaoling Luo
View Affiliations

Affiliations: Shenzhen Hornetcorn Biotechnology Co. Ltd, Shenzhen, Guangdong 518045, P.R. China, Laboratory Department, The Second Affliated Hospital of Nanhua University, Hengyang, Hunan 421001, P.R. China, MCH Hospital of Zhuhui, Hengyang, Hunan 421001, P.R. China, Changsha Medical University, Changsha, Hunan 410219, P.R. China
Published online on: July 11, 2016 https://doi.org/10.3892/ol.2016.4839
Pages: 2033-2037

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cell (DCs) are essential antigen processing and presentation cells that play a key role in the immune response. In this study, DCs were co‑cultured with cytokine‑induced killer cells (DC‑CIKs) in vitro to detect changes in cell proliferation, cell phenotype and cell cytotoxicity. The results revealed that the DCs were suitable for co‑culture with CIKs at day 7, and that cell quantity of DC‑CIKs was lower than that of CIKs until day 11, but it was significantly improved to 1.17‑fold that of CIKs at day 13. Flow cytometry was used to detect the cell phenotype of CIKs and DC‑CIKs. Compared with CIKs at day 13, the percentage of CD3+, CD3+CD4+, CD3+CD8+ and CD3+CD56+ T cells in DC‑CIKs was significantly improved 1.02, 1.79, 1.26 and 2.44‑fold, respectively. In addition, trypan blue staining analysis demonstrated that the cell viability of CIKs and DC‑CIKs was 96% and 98%, respectively. Furthermore, 3‑(4,5‑dimethylthiazol‑2‑yl)-2,5-diphenyltetrazolium bromide (MTT) analysis verified that CIK and DC‑CIK cytotoxicity in Hela cells was 58% and 80%, respectively, with a significant difference. Taken together, our results indicate that the cell proliferation, cell phenotype and antitumor activity of CIKs were all enhanced following co‑culture with DCs in vitro. These results are likely to be useful for DC‑CIK application in antitumor therapies.

View Figures

View References

1	Qu HQ, Zhou XS, Zhou XL and Wang J: Effect of DC-CIK cell on the proliferation, apoptosis and differentiation of leukemia cells. Asian Pac J Trop Med. 7:659–662. 2014. View Article : Google Scholar : PubMed/NCBI
2	Schmeel FC, Schmeel LC, Gast SM and Schmidt-Wolf IG: Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci. 15:14632–14648. 2014. View Article : Google Scholar : PubMed/NCBI
3	Wefers C, Lambert LJ, Torensma R and Hato SV: Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence. Gynecol Oncol. 137:335–342. 2015. View Article : Google Scholar : PubMed/NCBI
4	Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K, Duangsa-ard S, Sa-ngiamsuntorn K, Hongeng S and Maneechotesuwan K: Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells. PLoS One. 8:e789802013. View Article : Google Scholar : PubMed/NCBI
5	Introna M, Golay J and Rambaldi A: Cytokine induced killer (CIK) cells for the treatment of haematological neoplasms. Immunol Lett. 155:27–30. 2013. View Article : Google Scholar : PubMed/NCBI
6	Banchereau J and Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 5:296–306. 2005. View Article : Google Scholar : PubMed/NCBI
7	Thorne SH, Negrin RS and Contag CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science. 311:1780–1784. 2006. View Article : Google Scholar : PubMed/NCBI
8	Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 190:1669–1678. 1999. View Article : Google Scholar : PubMed/NCBI
9	Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
10	Mody N, Dubey S, Sharma R, Agrawal U and Vyas SP: Dendritic cell-based vaccine research against cancer. Expert Rev Clin Immunol. 11:213–232. 2015. View Article : Google Scholar : PubMed/NCBI
11	Frank MO, Kaufman J, Parveen S, Blachère NE, Orange DE and Darnell RB: Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med. 12:3382014. View Article : Google Scholar : PubMed/NCBI
12	Zhu H, Yang X, Li J, Ren Y, Zhang T, Zhang C, Zhang J, Li J and Pang Y: Immune response, safety and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int. 2014:6038712014. View Article : Google Scholar : PubMed/NCBI
13	Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, et al: The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 20:4305–4311. 2013. View Article : Google Scholar : PubMed/NCBI
14	Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, et al: Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 17:1679–1687. 2011. View Article : Google Scholar : PubMed/NCBI
15	Miao L, Run-Ming J and Yi J: T-Bet mediated anti-neoplastic effects of dendritic cell-cytokine induced killer cells in vitro. Iran J Pediatr. 22:43–51. 2012.PubMed/NCBI
16	Pan Y, Tao Q, Wang H, Xiong S, Zhang R, Chen T, Tao L and Zhai Z: Dendritic cells decreased the concomitant expanded Tregs and Tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells. PLoS One. 9:e935912014. View Article : Google Scholar : PubMed/NCBI
17	Lenahan C and Avigan D: Dendritic cell defects in patients with cancer: mechanisms and significance. Breast Cancer Res. 8:1012006. View Article : Google Scholar : PubMed/NCBI
18	Chen J, Wei Y, He J, Cui G, Zhu Y, Lu C, Ding Y, Xue R, Bai L, Uede T, et al: Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota. Sci Rep. 4:72592014. View Article : Google Scholar : PubMed/NCBI
19	Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE and Czerniecki BJ: Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med. 87:491–518. 2014.PubMed/NCBI
20	Gütgemann S, Frank S, Strehl J and Schmidt-Wolf IG: Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci. 5:Doc072007.PubMed/NCBI
21	Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C and Forman SJ: Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev. 157:231–240. 1997. View Article : Google Scholar : PubMed/NCBI
22	Linn YC and Hui KM: Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma. 44:1457–1462. 2003. View Article : Google Scholar : PubMed/NCBI
23	Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
24	Jäkel CE, Vogt A, Gonzalez-Carmona MA and Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res. 2014:8972142014.PubMed/NCBI
25	Zhang Y, Xia L, Zhang Y, Wang Y, Lu X, Shi F, Liu Y, Chen M, Feng K, Zhang W, et al: Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers. Expert Opin Biol Ther. 15:481–493. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhang Q, Liu XY, Zhang T, Zhang XF, Zhao L, Long F, Liu ZK and Wang EH: The dual-functional capability of cytokine-induced killer cells and application in tumor immunology. Hum Immunol. 76:385–391. 2015. View Article : Google Scholar : PubMed/NCBI
27	Bach M, Schimmelpfennig C and Stolzing A: Influence of murine mesenchymal stem cells on proliferation, phenotype, vitality, and cytotoxicity of murine cytokine-induced killer cells in coculture. PLoS One. 9:e881152014. View Article : Google Scholar : PubMed/NCBI
28	Chan WC and Linn YC: A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role. Cytotechnology. Dec 7–2014.(Epub ahead of print). PubMed/NCBI
29	Wang M, Cao JX, Pan JH, Liu YS, Xu BL, Li D, Zhang XY, Li JL, Liu JL, Wang HB and Wang ZX: Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. PLoS One. 9:e1126622014. View Article : Google Scholar : PubMed/NCBI
30	Salaun B, Yamamoto T, Badran B, Tsunetsugu-Yokota Y, Roux A, Baitsch L, Rouas R, Fayyad-Kazan H, Baumgaertner P, Devevre E, et al: Differentiation associated regulation of microRNA expression in vivo in human CD8⁺ T cell subsets. J Transl Med. 9:442011. View Article : Google Scholar : PubMed/NCBI
31	Schmeel LC, Schmeel FC, Coch C and Schmidt-Wolf IG: Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 141:839–849. 2015. View Article : Google Scholar : PubMed/NCBI
32	Xue CM, Chen C, Xu J, et al: Influence of some traditional Chinese medicines (TCMS) on cytokine-induced killer cells proliferation and anti-tumor features in vitro. Int J Res Ayurveda Pharm. 4:228–232. 2013. View Article : Google Scholar